Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2C-B or Apixaban

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Eliquis (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes:
2C-x series (1) · Phenethylamine (1) · Psychedelic (1) · [[:Category:Anticoagulants|Anticoagulant]] (1) · [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]] (1) · [[:Category:DOACs|Direct oral anticoagulant (DOAC)]] (1)
mechanism:
5-HT2A partial agonist (1) · '"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1)
uses:
None (1) · '"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1)
starting dose:
None (1) · NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1)
preparations:
None (1) · 2.5 mg, 5 mg tablets (1)
fda max:
None (1) · 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID (1)
routes:
insufflated (1) · Oral (2) · PR (1)
onset:
45-75 min (oral) (1) · Peak anticoagulant effect 3-4 hours (1)
duration:
12 hours (1) · 4-8 h (1)
halflife:
Not well characterized (1) · ~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1)
bioavailability:
Not well characterized (1) · ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1)
pregnancy:
None (1) · Not established (1)
legal:
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 2 results in range #1 to #2.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

2


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"